Roth Capital Starts Cempra, Inc. (CEMP) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Outlook Therapeutics (OTLK) halted, news pending
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Nasdaq lags on angst over AI spending ahead of earnings reports
Cempra (CEMP) to Offer $100M in Stock
January 5, 2015 4:04 PM ESTCempra, Inc. (Nasdaq: CEMP) announced its intention to offer and sell shares of its common stock with an aggregate public offering price of approximately $100 million in an underwritten public offering pursuant to its existing shelf registration statement. The company also intends to... More
Cempra (CEMP) Surges on Positive Phase 3 Results for Solitaire-Oral
January 5, 2015 7:08 AM ESTCempra (NASDAQ: CEMP) is sharply higher (+29%) in pre-open trading Monday after the company announced positive topline results from a global, pivotal Phase 3 clinical trial of solithromycin oral capsules (Solitaire-Oral) in the treatment of patients with community acquired bacterial pneumonia (CABP).
In the intent-to-treat population (ITT, all randomized patients), solithromycin met the primary objective of statistical non-inferiority (10% non-inferiority margin) of the early clinical response at 72 (-12/+36) hours after initiation of therapy compared to moxifloxacin. Solithromycin also met the secondary objectives of... More
Cempra (CEMP) PT Raised to $32 at Baird on Positive Solithromycin Data
January 5, 2015 6:27 AM ESTBaird analyst Brian Skorney reiterated an Outperform rating and boosted his price target on Cempra, Inc. (NASDAQ: CEMP) to $32.00 (from $21.00) after Solithromycin clears first phase 3 hurdle.
"We're encouraged by the top-line results posted by Cempra from its Solitaire-Oral study featuring solithromycin,"... More
